This article has been withdrawn at the request of the authors. The Publisher apologizes for any inconvenience this may cause. The full Elsevier policy on Article Withdrawal can be found at http://www.elsevier.com/locate/withdrawalpolicy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.humpath.2011.08.015 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Proviral Integration of Moloney Virus-2 (PIM-2) Expression Level as a Prognostic Marker in Patients with Acute Myeloid Leukemia.
Int J Gen Med
April 2022
Department of Clinical Pathology, Faculty of Medicine, Zagazig University, Zagazig, Al-Sharkia, Egypt.
Purpose: This study aimed to assess gene expression level as a prognostic marker in AML patients and to correlate the results with their clinical outcome.
Patients And Methods: This study was conducted on 50 de novo younger AML patients (median age 44). Quantitative real-time polymerase chain reaction (QRT-PCR) was used to assess the expression level of the gene.
CD33 Expression and Gentuzumab Ozogamicin in Acute Myeloid Leukemia: Two Sides of the Same Coin.
Cancers (Basel)
June 2021
Hematology Unit, S. Eugenio Hospital, ASL Roma 2, 00144 Rome, Italy.
Acute myeloid leukemia (AML), the most frequent acute leukemia in adults, has been historically treated with infusional cytarabine (ara-c) + daunorubicin (3 + 7) for at least 40 years. The first "target therapy" to be introduced was the monoclonal anti-CD33 gemtuzumab ozogamicin (GO) in 2004. Unfortunately, in 2010 it was voluntarily withdrawn from the market both for safety reasons related to potential liver toxicity and veno-occlusive disease (VOD) and because clinical studies failed to confirm the clinical benefit during induction and maintenance.
View Article and Find Full Text PDFDiscontinuation of tyrosine kinase inhibitors in CML patients in real-world clinical practice at a single institution.
BMC Cancer
December 2018
Department of Onco-Haematology, Portuguese Oncology Institute, Porto, Portugal.
Background: Most patients with chronic myeloid leukemia (CML) treated with tyrosine kinase inhibitors (TKIs) will relapse if treatment is withdrawn, but various trials have recently demonstrated that a significant proportion of patients who achieved a stable and deep molecular response (DMR) can stop therapy without relapsing. However, most information on treatment cessation was obtained from clinical trials with strict recruiting criteria.
Methods: We evaluated the outcome of 25 patients with CML that discontinued TKI therapy in our institute in real-world clinical practice.
Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.
Expert Rev Clin Pharmacol
June 2018
b Leukemia Service, Department of Medicine , Roswell Park Comprehensive Cancer Center, Buffalo , NY , USA.
Gemtuzumab ozogamicin (GO) is an antibody-drug conjugate consisting of a monoclonal antibody targeting CD33 linked to a cytotoxic derivative of calicheamicin. Despite the known clinical efficacy in relapsed/refractory acute myeloid leukemia (AML), GO was withdrawn from the market in 2010 due to increased early deaths witnessed in newly diagnosed AML patients receiving GO + intensive chemotherapy. In 2017, new data on the clinical efficacy and safety of GO administered on a fractionated-dosing schedule led to re-approval for newly diagnosed and relapsed/refractory AML.
View Article and Find Full Text PDFWITHDRAWN: Cytogenetics alteration in adult men involved in the recycling of electronic wastes.
Environ Int
March 2018
Institute of Radiation Medicine, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin Key Laboratory of Molecular Nuclear Medicine, Tianjin, China.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!